Vertex Pharmaceuticals traded at $299.23 this Wednesday August 17th, decreasing $3.77 or 1.24 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 4.60 percent. Over the last 12 months, its price rose by 53.63 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 286.27 by the end of this quarter and at 262.89 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
299.23
Daily Change
-1.24%
Yearly
53.63%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 141.44 -1.11 -0.78% 20.59%
Acadia Pharmaceuticals 17.06 0.10 0.59% 2.03%
Acorda Therapeutics 0.46 -0.01 -2.11% -87.45%
Agios Pharmaceuticals 26.22 -1.19 -4.34% -37.94%
Alnylam Pharmaceuticals 223.13 -5.02 -2.20% 12.96%
Amgen 250.58 -2.57 -1.02% 10.47%
Arrowhead Research 45.88 -1.75 -3.67% -23.24%
Biogen 217.58 -2.06 -0.94% -36.36%
Bluebird Bio 6.78 0.20 2.96% -62.55%
BioMarin Pharmaceutical 94.91 -0.12 -0.13% 25.64%
Bristol-Myers Squibb 74.56 0.43 0.58% 9.76%
Gilead Sciences 66.02 -0.31 -0.47% -8.25%
Intercept Pharmaceuticals 18.73 0.66 3.65% 31.72%
Incyte Corp 73.86 -1.10 -1.47% -0.91%
Insmed 25.77 -0.72 -2.72% 12.98%
Ionis Pharmaceuticals 43.88 -0.44 -0.99% 15.38%
J&J 167.58 0.01 0.01% -5.42%
Merck & Co 91.04 0.45 0.50% 17.03%
Moderna Inc 158.00 -9.96 -5.93% -60.38%
Neurocrine Biosciences 104.94 -1.17 -1.10% 14.31%
Novartis 81.23 0.25 0.31% -6.36%
Puma Biotechnology 3.19 -0.08 -2.45% -54.82%
Pfizer 49.27 -0.59 -1.18% -0.08%
PTC Therapeutics 51.17 -0.69 -1.33% 35.30%
Ultragenyx Pharmaceutical 47.25 -2.06 -4.18% -42.35%
Regeneron Pharmaceuticals 636.34 -12.36 -1.91% 0.12%
Roche Holding 316.65 1.00 0.32% -15.00%
Sanofi 81.67 -4.92 -5.68% -8.90%
Seattle Genetics 170.79 0.27 0.16% 7.57%
Sangamo BioSciences 5.89 -0.20 -3.28% -37.47%
Sarepta Therapeutics 109.00 1.17 1.09% 45.33%
United Therapeutics 221.63 -0.03 -0.01% 8.98%
Vertex Pharmaceuticals 299.23 -3.77 -1.24% 53.63%

Indexes Price Day Year
US500 4268 -31.16 -0.72% -3.00%
USND 12938 -164.43 -1.25% -10.93%
US400 2600 -35.43 -1.34% -2.52%
USNDX 13444 -164.35 -1.21% -9.51%

Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.